Indium (111In) capromab pendetide

From Wikipedia, the free encyclopedia

Indium (¹¹¹In) capromab pendetide^?
Monoclonal antibody
Type	Whole antibody
Source	Mouse
Target	prostatic carcinoma cells
Clinical data
Trade names	Prostascint
Legal status	?
Identifiers
CAS number	151763-64-3^N (capromab) 148805-91-8 (pendetide)
ATC code	V09IB04
ChEMBL	CHEMBL1201579^N
Chemical data
Formula	?
N (what is this?) (verify)

Indium (¹¹¹In) capromab pendetide (trade name Prostascint) is used to image the extent of prostate cancer.^[1] Capromab is a mouse monoclonal antibody which recognizes prostate specific membrane antigen (PSMA) from prostate cancer cells and normal prostate tissue. It is linked to pendetide, a derivative of DTPA.^[2] Pendetide acts as a chelating agent for the radionuclide indium-111. Following an intravenous injection of Prostascint, imaging is performed using single photon emission computed tomography (SPECT).^[1]

Early trials with yttrium (⁹⁰Y) capromab pendetide were also conducted.^[3]

References

↑ 1.0 1.1 Manyak, M. J. (2008). "Indium-111 capromab pendetide in the management of recurrent prostate cancer". Expert Review of Anticancer Therapy 8 (2): 175–122. doi:10.1586/14737140.8.2.175. PMID 18279057.
↑ WHO Drug Information
↑ Kahn, Daniel; J. Christopher Austin, Robert T. Maguire, Sara J. Miller, Jack Gerstbrein, Richard D. Williams (1999). "A Phase II Study of [⁹⁰Y] Yttrium-Capromab Pendetide in the Treatment of Men with Prostate Cancer Recurrence Following Radical Prostatectomy". Cancer Biotherapy & Radiopharmaceuticals 14 (2): 99. doi:10.1089/cbr.1999.14.99. Cite uses deprecated parameters (help)

v t e Diagnostic radiopharmaceuticals (V09)

Central nervous system	^99mTc (Exametazime) ¹²³I (Ioflupane Iofetamine Iomazenil) ¹⁸F (Florbetapir)

Skeletal system	^99mTc (Medronic acid)

Renal	¹²³I (Sodium iodohippurate)

Hepatic/reticuloendothelial	⁷⁵Se (SeHCAT)

Respiratory system	¹³³Xe ^81mKr

Cardiovascular system	^99mTc (Sestamibi Tetrofosmin) ¹¹¹In (Imciromab) ⁸²Rb (Rubidium chloride)

Inflammation/infection	^99mTc (Exametazime Sulesomab Tilmanocept) ¹¹¹In ⁶⁷Ga

Tumor	^99mTc (Arcitumomab Votumumab Hynic-octreotide) ¹¹¹In (Capromab pendetide Satumomab pendetide) ¹²⁵I (CC49) ¹²³I/¹³¹I (Iobenguane) ¹⁸F (Fludeoxyglucose Sodium fluoride)

Adrenal cortex	¹²³I/¹²⁵I (Iodocholesterol)

Radionuclides (including tracers)	positron (PET): ¹⁸F ¹¹C ¹³N ¹⁵O ⁶⁸Ga gamma ray/photon (SPECT/scintigraphy): ^99mTc ¹²³I ¹²⁵I ¹³¹I ¹¹¹In ⁵⁷Co ¹⁵³Sm ¹³³Xe ⁵¹Cr ^81mKr ²⁰¹Tl ⁶⁷Ga ⁷⁵Se

Monoclonal antibodies for tumors

Tumor ("-t(u[m])-")

Human ("-tumu-")	Adecatumumab Cixutumumab Conatumumab Daratumumab Drozitumab Duligotumab Dusigitumab Figitumumab Ganitumab Glembatumumab vedotin Intetumumab Iratumumab Lexatumumab Lucatumumab Mapatumumab Narnatumab Necitumumab Ofatumumab Olaratumab Panitumumab Patritumab Pritumumab Radretumab Rilotumumab Robatumumab Teprotumumab Tovetumab Vantictumab Votumumab Zalutumumab "-melu-" (melanoma): Flanvotumab

Mouse ("-tumo-")	Altumomab pentetate Anatumomab mafenatox Arcitumomab Bectumomab Blinatumomab CC49 Detumomab Ibritumomab tiuxetan Minretumomab Mitumomab Moxetumomab pasudotox Naptumomab estafenatox Nofetumomab merpentan Pemtumomab^† Pintumomab Racotumomab Satumomab pendetide Solitomab Taplitumomab paptox Tenatumomab Tositumomab 3F8 "-govo-" (ovarian tumor): Abagovomab · Igovomab · Oregovomab "-pro-" (prostate tumor): Capromab pendetide "-colo-" (colonic tumor): Edrecolomab · Nacolomab tafenatox

Chimeric ("-tuxi-")	Amatuximab Bavituximab Brentuximab vedotin Cetuximab Ensituximab Futuximab Girentuximab Indatuximab ravtansine Margetuximab Rituximab Siltuximab Ublituximab "-mexi-" (melanoma): Ecromeximab

Humanized ("-tuzu-")	Obinutuzumab Alemtuzumab Bevacizumab Bivatuzumab mertansine Cantuzumab mertansine Cantuzumab ravtansine Citatuzumab bogatox Clivatuzumab tetraxetan Dacetuzumab Dalotuzumab Elotuzumab^† Etaracizumab Farletuzumab Ficlatuzumab Gemtuzumab ozogamicin Imgatuzumab Inotuzumab ozogamicin Labetuzumab Lintuzumab Lorvotuzumab mertansine Matuzumab^§ Milatuzumab Nimotuzumab Ocaratuzumab Otlertuzumab Onartuzumab Oportuzumab monatox Parsatuzumab Pertuzumab Sibrotuzumab Simtuzumab Tacatuzumab tetraxetan Tigatuzumab Trastuzumab Tucotuzumab celmoleukin Veltuzumab Vorsetuzumab mafodotin

Rat/mouse hybrid ("-tumaxo-")	Catumaxomab Ertumaxomab

Chimeric + humanized ("-tuxizu-")	Ontuxizumab

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.